Intravenous iron therapy in patients with chronic kidney disease: recent evidence and future directions

Iain C. Macdougall

Department of Renal Medicine, King’s College Hospital, London, UK

Correspondence and offprint requests to: Iain C. Macdougall; E-mail: iain.macdougall@nhs.net

Abstract

Current recommendations for the use of intravenous iron therapy in the management of anaemia in patients with chronic kidney disease (CKD) are based on limited clinical evidence. Since the publication of the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Anaemia in Chronic Kidney Disease in 2012, a number of randomized clinical trials [notably, the Ferinject Assessment in Patients with Iron Deficiency Anaemia (FIND-CKD) and Randomized Trial to Evaluate IV and Oral Iron in Chronic Kidney Disease (REVOKE) trials] and observational studies have been completed, and a further large clinical trial—Proactive IV Iron Therapy in Dialysis Patients (PIVOTAL)—is currently underway. In this article, the implications of the findings from these recent studies are discussed and the critical evidence gaps that remain to be addressed are highlighted.

Key words: CKD, clinical trial, epidemiology, ESRD, iron

Introduction

Iron deficiency anaemia is a common and clinically important concern in patients with chronic kidney disease (CKD). In this patient population, chronic inflammation may lead to increased hepcidin production, in turn inhibiting both the uptake of dietary iron and the mobilization of stored iron from the reticuloendothelial system to circulating transferrin [1]. Insufficient dietary iron uptake may be compounded by poor appetite or dietary restrictions, and intestinal bleeding may result in increased iron losses [2–4]. The problem is exacerbated in patients receiving dialysis who experience significant additional iron losses due to blood remaining in the dialyser circuit after treatment. Patients with CKD receiving treatment with erythropoiesis-stimulating agents (ESAs) are very prone to iron deficiency due to the increased demand for iron to support erythropoiesis, and indeed iron deficiency is the most commonly identified cause of hyporesponsiveness to ESA therapy in dialysis patients [5, 6]. As a result, iron therapy, either alone or in combination with ESA treatment, has been an important component of the management of anaemia in patients with CKD for many years.

The chapter in this supplement authored by Berns provides a detailed discussion of the 2012 Kidney Disease: Improving Global Outcomes (KDIGO) guideline recommendations for the use of iron to treat anaemia in CKD, while the chapter by Roger discusses current opinion regarding the application of the guideline in clinical practice. Both of these chapters highlight the fact that the quality of clinical evidence underpinning the guideline recommendations is relatively poor, with the result that different interpretations are possible. In the 4 years since the publication of the guideline, several new randomized controlled trials (RCTs) have been completed, most notably the Ferinject Assessment in Patients with Iron Deficiency Anaemia (FIND-CKD) [7, 8] and Randomized Trial to Evaluate IV and Oral Iron in Chronic Kidney Disease (REVOKE) [9] studies, while another large RCT, Proactive IV Iron Therapy in Dialysis Patients (PIVOTAL), is currently in progress. In addition, a number of relevant observational studies have been published. The aim

Received: February 14, 2017. Editorial decision: February 15, 2017
© The Author 2017. Published by Oxford University Press on behalf of ERA-EDTA.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
of this chapter is to summarize the findings from these more recent studies and evaluate their implications for the management of iron deficiency anaemia in patients with CKD.

Iron therapy in patients with CKD: the evidence base for the 2012 KDIGO guideline

The 2012 KDIGO guideline recommends considering a trial of intravenous (IV) or oral iron in patients with CKD for whom an increase in haemoglobin levels without starting ESA therapy is desired (or when a decrease in the current ESA dose is desired), if transferrin saturation (TSAT) levels are ≤30% and serum ferritin levels are ≤500 μg/L. In patients with non-dialysis-dependent CKD (CKD-ND), it is suggested that the selection of iron administration route (oral versus IV) should be made based on the severity of anaemia, availability of venous access, response or lack of response to prior oral iron therapy, previously observed adverse events (AEs), patient adherence and cost; in patients with end-stage CKD (CKD-SD) receiving regular dialysis, oral iron is not recommended.

The recommendation to use IV rather than oral iron in CKD-SD patients was supported by a number of clinical studies in both haemodialysis and peritoneal dialysis patients (although the number of studies in peritoneal dialysis patients is very low), demonstrating a greater haemoglobin response with IV iron compared with oral iron [10–15]. Moreover, iron therapy, and in particular IV iron therapy, was found to improve the response to ESA treatment and reduce ESA requirements in this patient population [10, 11, 13, 15–21]. At the time of guideline publication, data showing greater efficacy of IV iron compared with oral iron with respect to erythropoietic response in patients with CKD-ND were more limited [22–28]. In both patient populations, the studies on which guideline recommendations were based were generally very short in duration and involved only small numbers of patients such that no conclusions could be drawn with respect to long-term efficacy or safety of IV versus oral iron.

At the time the guidelines were written, very little clinical evidence existed to support the suggested upper limits for iron status targets [29]. The recommendation to discontinue IV iron therapy in patients with a serum ferritin >500 μg/L was based mainly on the reported potential for hepatic deposition of iron at higher ferritin levels, as well as the potential for exacerbation of oxidative stress or infections [30–32]. While serum ferritin and TSAT are the favoured markers for assessing iron status, serum ferritin is an acute-phase reactant and levels may be elevated if inflammation is present. Furthermore, hepcidin-mediated blockade of iron mobilization from the reticuloendothelial system may also contribute to circumstances where patients have elevated serum ferritin levels but low TSAT. Results from the Dialysis Patients’ Response to IV Iron with Elevated Ferritin (DRIVE) study suggested that iron therapy may lead to increases in haemoglobin levels and reduced ESA requirements even in patients with serum ferritin levels in excess of 500 μg/L [20, 33]. However, the study was conducted in only 134 dialysis patients, and the initial period of follow-up was only 6 weeks, with a further 6-week observational extension (DRIVE-II). Clearly, the long-term safety of IV iron administration in patients with elevated serum ferritin could not be ascertained from such a short follow-up period.

Observational data on the safety of iron therapy that were available at the time of guideline publication (but not considered by the panel when making recommendations) were also conflicting: one large US study showed no increase in dialysis patient mortality with iron doses of ≤1000 mg over 6 months [34], while a second study showed an increase in mortality in dialysis patients receiving doses of >400 mg/month [35].

New evidence: the FIND-CKD and REVOKE trials

Since the publication of the KDIGO guideline, several new studies have added to the clinical evidence base in support of the efficacy and short-term safety of IV iron therapy in patients with CKD-ND and CKD-SD [36–39]. A recent meta-analysis by Shepselovich et al. [40], updating their original 2008 analysis [41], assessed data from 24 RCTs—13 of patients with CKD-ND and 11 of patients with CKD-SD—and concluded that patients treated with IV iron were more likely to achieve a haemoglobin increase of >1 g/dL than patients treated with oral iron (risk ratios 1.61 and 2.14 for CKD-ND and CKD-SD, respectively). Rates of mortality and serious AEs (SAEs)/AEs were found to be similar for the IV and oral iron groups, although IV iron administration was associated with a higher risk of hypotension but fewer gastrointestinal AEs. Similarly, in a meta-analysis of RCTs that evaluated IV iron for any clinical indication, treatment with IV iron was not found to be associated with increased risk of SAEs or infections versus comparator (placebo, no iron, oral iron or intramuscular iron), although the median follow-up time for the 103 studies assessed was only 8 weeks [42] (Table 1).

Two recent studies that were designed to inform with respect to the long-term efficacy and safety of IV iron in patients with CKD-ND were the FIND-CKD and REVOKE trials. FIND-CKD, published in 2014 [8], was designed to evaluate the efficacy of oral or IV iron (ferric carboxymaltose) to delay the onset of, or reduce the use of, ESA or other anaemia management in patients with CKD-ND and iron-deficiency anaemia when using targeted ferritin levels to determine iron dosing. A total of 626 patients across 193 sites in 20 countries were randomized to receive either high-dose IV ferric carboxymaltose (1000 mg every 4 weeks) targeting ferritin 400–600 μg/L, low-dose IV ferric carboxymaltose (200 mg every 4 weeks) targeting ferritin 100–200 μg/L, or oral iron (200 mg daily), and were followed over 56 weeks. The primary endpoint of the study was initiation of other anaemia management (ESA, other iron therapy, transfusion) or two consecutive haemoglobin measurements <10 g/dL during weeks 8–52. This endpoint occurred in 23.5, 32.2 and 31.8% of patients in the high-ferritin ferric carboxymaltose, low-ferritin ferric carboxymaltose and oral iron groups, respectively. The difference between the high-ferritin ferric carboxymaltose and oral iron groups was statistically significant [hazard ratio (HR), 0.65; 95% confidence interval (CI) 0.44–0.95; P = 0.025]. The increase in mean haemoglobin level from baseline to month 12 was significantly greater for the high-ferritin ferric carboxymaltose group versus the oral iron group, and the haematological response was also faster. Quality of life (QOL), as measured by the SF-36 instrument, did not show significant differences across groups, and AE and SAE rates were similar in all groups.

The primary objective of the REVOKE trial published 2015 [9] was to evaluate the effects of oral or IV iron on kidney function in patients with CKD-ND (stage 3/4) and iron-deficiency anaemia. A total of 136 subjects at a single centre in the USA were randomized to receive open label oral ferrous sulphate (325 mg tablets containing 65 mg elemental iron, three times daily for 8 weeks; n = 69) or IV iron sucrose (200 mg every 2 weeks for total of 1 g; n = 67); patients were followed for 2 years. No difference in the rate of measured glomerular filtration rate (mGFR) decline between groups was observed—i.e. IV iron was not
Table 1. Summary of RCTs of IV iron in patients with non-dialysis-dependent and dialysis-dependent CKD

| Reference | Treatment | n | Follow-up | Study conclusions |
|-----------|-----------|---|-----------|-------------------|
| **Studies in patients with dialysis-dependent CKD** | | | | |
| Fishbane et al. 1995 [10] | IV iron dextran versus oral iron | 52 (HD) | 4 months | Hb response to IV iron superior to oral iron, reduced ESA requirements with IV iron |
| Macdougall et al. 1996 [13] | IV iron dextran versus oral ferrous sulphate versus no iron | 37 (HD) | 4 months | Enhanced Hb response to ESA and lower ESA requirements with IV iron compared with oral iron or no iron |
| Singh et al. 2006 [15] | IV iron sucrose versus no iron | 96 (PD) | 8 weeks | Peak Hb higher and other anaemia interventions occurred later/less often in patients receiving IV iron |
| Coyne et al. 2007 [33] | IV sodium ferric gluconate versus no iron | 134 (HD) | 6 weeks | In patients receiving an adequate ESA, Hb response greater at 6 weeks in IV iron group than control, irrespective of serum ferritin levels (<800 µg/L versus >800 µg/L) |
| Kapoian et al. 2008 [20] | IV sodium ferric gluconate versus no iron | 118 (HD) | 6 weeks | Reduced ESA use with IV iron compared with no iron, fewer AEs with IV iron |
| Li and Wang 2008 [11] | IV iron sucrose versus oral ferrous succinate | 136 (HD) | 8 weeks | Hb response to IV iron superior to oral iron, reduced ESA requirements with IV iron, fewer AEs with IV iron |
| Li and Wang 2008 [12] | IV iron sucrose versus oral ferrous succinate | 46 (PD) | 8 weeks | Hb response to IV iron superior to oral iron, no difference in AEs |
| Provenzano et al. 2009 [14] | IV ferumoxytol versus oral ferrous fumarate | 230 (HD) | 5 weeks | Hb response to IV iron superior to oral iron, no difference in AEs |
| Charytan et al. 2013 [37] | IV ferric carboxymaltose versus standard medical care (oral/IV/no iron) | 97 (CKD-HD subgroup) | 30 days | No significant difference in primary safety outcome (number of AEs), although more SAEs in standard medical care group; no significant difference in secondary efficacy outcomes |
| Bhandari et al. 2015 [36] | IV iron isomaltoside 1000 versus IV iron sucrose | 351 (HD) | 6 weeks | Similar efficacy with respect to Hb in range; significantly greater increase in ferritin from baseline to weeks 1, 2 and 4 and in reticulocyte count at week 4 for iron isomaltoside group; frequency and severity of AEs similar |
| **Studies in patients with non-dialysis-dependent CKD** | | | | |
| Silverberg et al. 2001 [4] | IV iron sucrose with versus without ESA | 90 | 1 year | Target Hb maintained with low dose ESA in two-thirds of patients, and with no ESA in one-third |
| Stoves et al. 2001 [27] | IV iron sucrose versus oral ferrous sulphate | 45 | 6 months | No difference between IV iron and oral iron in patients |
| Aggarwal et al. 2003 [23] | IV iron dextran versus oral ferrous sulphate | 40 | 3 months | IV iron superior to oral iron, no difference in AEs |
| Charytan et al. 2005 [24] | IV iron sucrose versus oral ferrous sulphate | 96 | 6 weeks | IV iron superior to oral iron, no difference in AEs |
| Van Wyck et al. 2005 [28] | IV iron sucrose versus oral ferrous sulphate | 188 | 8 weeks | IV iron superior to oral iron, no difference in AEs, proportion of patients achieving Hb targets unaffected by ESA use |
| Agarwal et al. 2006 [22] | IV sodium ferric gluconate versus oral ferrous sulphate | 75 | 6 weeks | More rapid repletion of iron stores and improved QOL with IV iron compared with oral iron |
| Spinowitz et al. 2008 [26] | IV ferumoxytol versus oral iron | 304 | 5 weeks | IV iron superior to oral iron, no difference in AEs, increased Hb response when ESA given concurrently |
| Bailie et al. 2010 [43] | IV ferric carboxymaltose versus placebo | 598 subjects with IDA; 70 with CKD | 2 weeks | Minimal risk of hypersensitivity or adverse drug reaction with IV iron |
| McMahon et al. 2010 [44] | IV iron sucrose versus oral ferrous sulphate | 100 | 52 weeks | Maintaining iron stores above physiological level does not confer greater Hb response in ESA-naïve, iron-replete patients with Hb >11 g/dL |

(continued)
found to accelerate (or delay) a decline in kidney function; statistically significant improvements in haemoglobin that were sustained for 24 months were observed for both the IV and oral iron groups with no significant between-group differences. However, a higher risk of SAEs [adjusted incidence rate ratio (aIRR), 1.60; 95% CI 1.28–2.00; P < 0.0001], cardiovascular (CV) SAEs (aIRR, 2.51; 95% CI 1.56–4.04; P < 0.001) and infection resulting in hospitalization (aIRR, 2.12; 95% CI 1.24–3.64; P < 0.006) in the IV iron group resulted in early termination of the study.

While both of these studies represent a significant advance over previous RCTs in that they involved larger numbers of patients and much longer follow-up periods, the findings were starkly contrasting, with the authors drawing essentially opposing conclusions. The investigators of the REVOKE trial concluded that use of IV iron resulted in elevated risk of infection and CV complications and that in patients with CKD-ND, oral iron may be the preferred first-line treatment for iron deficiency anaemia. In contrast, the FIND-CKD investigators concluded that the use of IV iron to target higher ferritin levels may contribute to improved anaemia management in this patient population, with no safety concerns in terms of CV events or infectious episodes [45].

Potential explanations for the differences in findings from these studies have been discussed in several commentaries [46–48]. One key difference between the two trials is that the dose of oral iron used in the FIND-CKD study was significantly lower than that used in the REVOKE study; this could potentially explain the conflicting conclusions drawn with respect to the efficacy of IV versus oral iron, but would not explain the discrepancy in the safety data. Another point of contention that may have bearing on the interpretation of findings is the appropriateness of adjustments for baseline patient differences that were applied in the analysis of data from the REVOKE study, particularly as some of the key safety findings only achieved statistical significance following such adjustment. In addition, the reporting and methods of adjudication of AEs differ between the two studies, further complicating their comparison. However, a recent post-hoc analysis of data from FIND-CKD examining the incidence of AEs using the same approach as the REVOKE analysis—counting individual AEs as separate events when a patient experienced multiple events—also showed no difference between treatment groups [45]. Other, more fundamental differences between the two studies include the fact that they used different iron formulations (iron sucrose versus ferric carboxymaltose) and were undertaken in different countries (USA versus multiple European countries/Australia).

### New evidence: observational studies

In addition to the data from RCTs, a number of epidemiologic analyses pertaining to IV iron safety and efficacy have been published in the years since the release of the KDIGO guideline. An important consideration when interpreting findings from observational studies is that, by nature, such studies may be subject to confounding for various reasons, the most obvious in this case being that it is often the sickest patients who are given the greatest amounts of IV iron. Nonetheless, such studies can still provide insights into anaemia management trends as well as the efficacy and safety of IV iron therapy as applied in real-world clinical practice (Table 2).

An analysis of data from the Dialysis Outcomes and Practice Patterns Study (DOPPS) collected between 2002 and 2011, and considering 32,435 patients in 12 countries, showed an

| Table 1. (continued) |
|----------------------|
| Reference | Treatment | n | Follow-up | Study conclusions |
| Qinibi et al. 2011 [25] | IV ferric carboxymaltose versus oral ferrous sulphate | 255 | 8 weeks | IV iron more effective than oral iron, fewer AEs with IV iron, increased Hb response when ESA given concurrently |
| Charytan et al. 2013 [37] | IV ferric carboxymaltose versus standard medical care (oral/IV/no iron) | 416 (CKD-ND subgroup) | 30 days | No significant difference in primary safety outcome (number of AEs), although more SAEs in standard medical care group; significant difference in secondary efficacy outcomes |
| Macdougall et al. 2014 [8] | IV ferric carboxymaltose versus oral ferrous sulphate | 626 | 56 weeks | Ferric carboxymaltose targeting ferritin 400–600 μg/L more effective than oral iron at reducing/delaying onset of other anaemia management or consecutive Hb values <10 g/dL; no difference in AEs |
| Onken et al. 2014 [39] | IV ferric carboxymaltose versus IV iron sucrose | 2585 | 56 days efficacy; 120 days safety | More subjects receiving ferric carboxymaltose versus iron sucrose achieved increase in Hb >1g/dL; no significant difference in composite safety endpoint |
| Agarwal et al. 2015 [9] | IV iron sucrose versus oral ferrous sulphate | 136 | 2 years | No difference between groups in slope of mGFR change; IV iron associated with increased risk of CV events and infection |
| Kalra et al. 2015 [38] | IV iron isomaltoside 1000 versus oral ferrous sulphate | 351 | 8 weeks | Greater increase in Hb with IV iron from week 3 to week 8; serum ferritin and TSAT also significantly increased with IV iron; ADRs similar; more patients in oral iron group withdrew from study due to ADRs |

ADR, adverse drug reaction; Hb, haemoglobin; HD, haemodialysis; PD, peritoneal dialysis; IDA, iron deficiency anaemia.
Table 2. Summary of observational studies of IV iron in patients with non-dialysis-dependent and dialysis-dependent CKD (2013–present)

| Reference            | Study population                              | n    | Study design                                                                 | Study conclusions                                                                 |
|----------------------|-----------------------------------------------|------|------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| Brookhart et al. 2016 | Medicare ICHD patients (2004–05)              | 66 207 | Comparison of short-term safety of IV sodium ferric gluconate versus iron sucrose; 1-month exposure period; outcomes (all-cause mortality, infection-related and CV hospitalization and mortality) assessed over 3-month follow-up period | No difference in mortality outcomes Among CVC patients, slightly reduced risk of infection-related events in ferric gluconate patients Bolus dosing associated with increased infection-related events in both groups |
| Freburger et al. 2016 | ICHD patients of large US dialysis organization (2008–10) | 13 039 | Iron and ESA dosing assessed during 1-month and 2-week exposure periods; HRQOL measured over 3-month outcome period | In patients with low-baseline Hb, higher ESA dosing and bolus iron dosing associated with higher HRQOL scores |
| Airy et al. 2015      | USRDS, incident HD patients (2009–11)         | 14 206 | Comparison of HD facilities switching from iron sucrose or ferric gluconate to ferumoxytol with facilities that did not switch; incident patients at these facilities were followed until censoring, facility switch to different iron formulation or end of study (31 Dec 2011); outcomes assessed were all-cause mortality, CV hospitalization/mortality, infectious hospitalization/mortality | No difference in outcomes between facilities that switched to ferumoxytol and those that did not |
| Bailie et al. 2015    | DOPPS facility HD patients (2009–11)          | 32 435 | Assessed association between total prescribed IV iron dose over first 4 months in study with clinical outcomes (mortality, cause-specific mortality) | Increased risk of mortality for patients receiving 300–399 (13%) or 400+ mg/month (18%) compared with 100–199 mg/month; associations with cause-specific mortality and hospitalization similar |
| Ishida et al. 2015    | USRDS ICHD patients (2010)                    | 22 820 | Comparison of outcomes for patients receiving versus not receiving IV iron while in hospital for bacterial infection | Receipt of IV iron not associated with higher 30-day mortality or readmission for infection |
| Karaboyas et al. 2015 | DOPPS facility patients (2009–13)             | 9735  | Trends in mean ferritin, haemoglobin, IV iron dose and ESA dose from 2009 to 2013 assessed among patients at 91 DOPPS facilities | IV iron increased from 220 mg/month in 2009/10 to 280 mg/month in 2011 then declined back to 200 mg/month in 2012–13; mean ferritin increased from 601 ng/mL in Q3 2009 to 887 ng/mL in Q1 2012; increase in ferritin not solely due to iron dosing practices |
| Kuo et al. 2015       | Taiwan National Health Insurance Research Database, CKD-ND patients (2000–09) | 31 971 | Prospective cohort study of patients with creatinine >6 mg/dL, haematocrit <28%, treated with ESA; patients receiving versus not receiving IV iron within 90 days of starting ESA compared; outcomes assessed: death before dialysis initiation, hospitalization | Iron supplementation associated with 15% reduction in mortality and reduction in risk of hospitalization but higher risk of faster progression to ESRD |
| Tangri et al. 2015    | HD patients of Dialysis Clinic Inc. (2003–08) | 9544  | Iron exposure assessed over 1-, 3- and 6-month time windows; incident hospitalizations assessed during 30-day outcome window | Higher cumulative dose of IV iron not associated with increased risk of hospitalization |
| Freburger et al. 2014 | Medicare HD patients of small US dialysis provider | 6505  | Iron dosing patterns (bolus, maintenance, no iron) assessed during 1-month exposure windows; | Bolus iron dosing associated with increased risk of infection-related hospitalization and use of IV antibiotics; no association |
| Reference             | Study population                                                                 | n       | Study design                                                                                                                                  | Study conclusions                                                                                     |
|-----------------------|-----------------------------------------------------------------------------------|---------|-----------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|
| Miskulin et al. 2014  | Incident HD patients of Dialysis Clinic Inc. (2003–08)                             | 14 078  | outcomes assessed over 3-month follow-up period                                                                                               | between dosing practice and CV outcomes                                                              |
|                       | Iron exposure assessed over 1-, 3- and 6-month time windows; all-cause, CV and infection-related mortality assessed during 30-day outcome window. |         | Receipt of ≤1050 mg iron in 3 months or ≤2100 mg in 6 months not associated with all-cause, CV or infection-related mortality                |
|                       |                                                                                    |         | Receipt of >1050 mg iron in 3 months or >2100 mg in 6 months possibly associated with infection-related mortality (non-statistically significant) |
| Schiller et al. 2014  | Patients of three US dialysis chains                                              | 8666    | Patients treated with ferumoxytol at any time in 12-month period assessed; efficacy and safety outcomes considered                          | Ferumoxytol effective in increasing and maintaining Hb with AE profile similar to that reported in clinical trials |
| Bailie et al. 2013     | DOPPS facility patients (1999–2011)                                               | 32 192  | Trends in iron use and associations of IV iron dose with ferritin and TSAT assessed                                                          | IV iron use varied by country and increased over 2009–11 in most countries; increases in ferritin but not TSAT also observed |
| Brookhart et al. 2013  | HD patients of large dialysis provider (2004–08)                                  | 117 050 | Iron dosing patterns (bolus versus maintenance) assessed over 1-month exposure periods; mortality and infection-related hospitalization assessed n subsequent 3 months | Bolus iron dosing associated with increased risk of infection-related hospitalization and mortality; maintenance iron dosing not associated with increased risk for adverse outcomes compared with no iron |
| Kshirsagar et al. 2013 | HD patients of large dialysis provider (2004–08)                                  | 117 050 | Compared bolus versus maintenance and high versus low iron dose during 1-month exposure period and 3-month follow-up period; outcomes assessed: MI, stroke and CV mortality | Large doses of IV iron were not associated with increased risk of short-term CV morbidity and mortality |
| Kshirsagar et al. 2013 | HD patients of large dialysis provider (2004–08)                                  | 117 050 | Compared bolus versus maintenance and high versus low iron dose during 1-month exposure period and 6-week follow-up period; outcomes assessed: Hb, ESA dose, TSAT, serum ferritin | Large doses of IV iron associated with improved measures of anaemia management |
| Miskulin et al. 2013   | HD patients from medium-sized US dialysis provider (2004–10)                      |         | Indicators of anaemia management assessed in HD patients over 2004–07, 2007–09 and 2010                                                        | Median proportion of patients with Hb >12 g/dL and median weekly ESA doses declined sharply in 2010; iron doses, serum ferritin and TSAT increased over time |

DOPPS, Dialysis Practice Patterns and Outcomes Study; Hb, haemoglobin; HD, haemodialysis; HRQOL, health-related quality of life; ICHD, in-centre haemodialysis.

![Fig. 1. Proactive IV Iron Therapy in Dialysis Patients (PIVOTAL) Trial Design. ESA, erythropoiesis-stimulating agent; HD, haemodialysis; HF, heart failure; IV, intravenous; MI, myocardial infarction; R, randomisation; TSAT, transferrin saturation.](image_url)
association (albeit fairly weak) between high IV iron dose and mortality [52]. Compared with patients receiving 100–199 mg/month, mortality was higher for those receiving 300–399 mg/month (HR, 1.13; 95% CI 1.00–1.27) and 400–699 mg/month (HR, 1.18; 95% CI 1.07–1.30). Associations with cause-specific mortality (CV, infection, other) followed a similar pattern, and receipt of 300 mg/month or more was also associated with increased risk of hospitalization (HR, 1.12; 95% CI 1.07–1.18) versus 100–199 mg/month. In contrast, results of an analysis of data from the Developing Evidence to Inform Decisions about Effectiveness (DEcIDE)-ESRD study considering 14,078 patients initiating dialysis between 2003 and 2008 showed no association between receipt of cumulative doses <1050 mg in 3 months or <2100 mg in 6 months with all-cause, CV or infection-related mortality [58]. A second analysis of data from the DEcIDE-ESRD study also showed no association between iron dose level during 1-, 3- or 6-month exposure windows and risk of all-cause hospitalization or death among a cohort of incident haemodialysis patients (n = 9544) [56].

Several studies have examined outcomes in patients receiving bolus versus maintenance IV iron dosing. Notably, Brookhart et al. showed that among 117,050 Medicare patients dialysing at a large dialysis organization, bolus dosing (>100 mg iron in at least two consecutive dialysis sessions and total dose with potential to exceed 600 mg within 30 days) was associated with a small increase in relative risk of infection-related hospitalizations compared with maintenance dosing, resulting in 25 additional events per 1000 patient-years [61]; this association was found to be most pronounced in patients dialysing with a central venous catheter. Similar results were obtained in a study of 6605 patients of a small dialysis organization in which bolus dosing during a 1-month exposure period was found to be associated with a significant increase in relative risk of hospitalization for infection and receipt of IV antibiotics in the following 3 months; again associations were more pronounced in patients dialysing with catheters [57]. Infection risk associated with IV iron therapy was also assessed in a recent study of United States Renal Data System (USRDS) data: among a cohort of Medicare beneficiaries on incident haemodialysis who received IV iron in the 14 days prior to a hospitalization for bacterial infection, no association was observed between receipt of IV iron at any point during the hospitalization and 30-day mortality, mean length of hospital stay or a composite measure of readmission for infection or death within 30 days of discharge [53]. The authors of the study concluded that their findings did not support the withholding of IV iron upon hospitalization for bacterial infection, although they noted that the majority of IV iron administered was received on the day of admission, limiting the ability to draw conclusions about the longer-term use of IV iron during the course of infection.

Observational analyses of outcomes in CKD-ND patients have suggested potential benefits of initiating IV iron therapy prior to dialysis onset. One prospective study found that CKD-ND patients who were treated with ESA and also initiated IV iron supplementation had a lower risk of all-cause death than those who did not receive iron [55]. In this study, the risk of hospitalizations was also lower, although the risk of faster progression to end-stage renal disease (ESRD) was higher. Similarly, a small retrospective study of 102 patients initiating dialysis showed that those who received IV iron and ESA prior to onset of dialysis had higher haemoglobin levels and greater left ventricular ejection fraction at the time of dialysis initiation than patients who received oral iron and ESA therapy [65].

In summary, findings from observational studies have also been equivocal with respect to the long-term safety of IV iron (in particular, mortality and infection risk). While the differing findings may well be explained by differences in study design and patient populations assessed, the lack of a clear consensus again emphasizes the need for additional clinical data.

**Future prospects: the Proactive IV Iron Therapy in Dialysis Patients (PIVOTAL) trial**

One ongoing study that may prove to be informative is the PIVOTAL trial (EudraCT number 2013-002267-25). This study is the first to assess the long-term safety and efficacy of the currently accepted practices of liberal IV iron use in patients with CKD-5D. The specific objective of the study is to compare proactive high-dose and reactive low-dose IV iron regimens with respect to all-cause mortality and incidence of non-fatal CV endpoints as well as ESA dose requirements, the need for transfusions, incidence of infections and other complications of haemodialysis and indicators of QOL. The trial is a multicentre, prospective, open-label, two-arm RCT, enrolling 2080 haemodialysis patients (new to dialysis, or on dialysis for <12 months) at 50 dialysis units across the UK. Patients included in the study must be at least 18 years of age, receiving ESA therapy, and have serum ferritin levels <400 μg/L and TSAT <30% at baseline. Key exclusion criteria are life expectancy of <12 months, scheduled transplant within 12 months, C-reactive protein levels >50 mg/L, and presence of active infection or malignancy.

Study subjects are being randomized into two treatment arms: Those in the proactive IV iron arm will receive 400 mg of iron sucrose monthly provided that ferritin levels are <700 μg/L; iron dose will be withheld if ferritin levels are >700 μg/L and/or TSAT levels are >40%. Subjects in the reactive IV iron arm will receive 200 mg iron sucrose if serum ferritin levels are <100 μg/L, regardless of TSAT levels, and will receive 100 mg IV iron sucrose if ferritin levels are >100 μg/L, with TSAT <20%; iron will be withheld if ferritin levels are >200 μg/L and TSAT levels are >20% (Figure 1).

The primary endpoint of the study is time to all-cause death or a composite of non-fatal CV events [myocardial infarction (MI), stroke or hospitalization for heart failure (HF)]. Secondary efficacy endpoints include: incidence of all-cause death and a composite of MI, stroke and hospitalization for HF as recurrent events; time to (and incidence of) all-cause death, composite CV event, MI, stroke, hospitalization for HF; ESA dose requirements; transfusion requirements; and patient functioning and QOL evaluated using the EuroQOL 5 dimensions questionnaire (EQ-SD) and the Kidney Disease Quality of Life (KDQOL) instrument. Secondary safety endpoints to be assessed are incidence of vascular access thrombosis, all-cause hospitalization, hospitalization for infection and infectious episodes, as well as incidence of SAEs, adverse drug reactions and suspected unexpected serious adverse reactions. Tertiary endpoints to be assessed include cumulative iron dose as well as haemoglobin, mean cell volume, red cell distribution width, ferritin, TSAT and platelet levels.

The trial is event-driven and evaluation of outcomes will be conducted only once the required number of events are accrued (follow-up time of ~2–4 years is expected). At the time of writing, all 2080 patients have been recruited and randomized to the trial, and follow-up is ongoing. It is expected that the results of this trial will not be available until 2018, but it is likely that the data from this trial will significantly impact future iron management in CKD patients.

**Concluding remarks**

Guidelines on iron management in CKD patients are somewhat dated, conflicting and based on sparse evidence. Two new RCTs

in non-dialysis CKD patients (FIND-CKD and REVOKE) significantly improve the quality of the evidence base, but unfortunately produced conflicting results, which leaves us as confused as ever. Observational data are hypothesis-generating, but of limited clinical value due to significant confounding; moreover, the results of the new observational studies published since the 2012 KDIGO guideline are also conflicting. The PIVOTAL study seeks to fill the evidence gap, but results are not due until 2018.

Acknowledgements

The author thanks Abigail Hunt, PhD, an employee of DaVita Clinical Research, Minneapolis, MN, USA, for medical writing and editorial support in the preparation of this article.

Funding

Funding for medical writing support was provided by Vifor Pharma.

Conflict of interest statement

I.C.M. has received speaker and consultancy fees, as well as research funding from a number of IV iron manufacturers, including AMAG, Pharmacosmos and Vifor Pharma.

References

1. Wish JB. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 2006; 1 Suppl 1: 54–58
2. Fishbane S, Pollack S, Feldman HI et al. Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988–2004. Clin J Am Soc Nephrol 2009; 4: 57–61
3. Gotloib L, Silverberg D, Fudin R et al. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Nephrol 2006; 19: 161–167
4. Silverberg DS, Blum M, Agbaria Z et al. The effect of IV iron alone or in combination with low-dose erythropoietin in the rapid correction of anaemia of chronic renal failure in the predialysis period. Clin Nephrol 2001; 55: 212–219
5. Horl WH. Non-erythropoietin-based anaemia management in chronic kidney disease. Nephrol Dial Transplant 2002; 17 Suppl 11: 35–38
6. Li S, Foley RN, Gilbertson DT et al. Clinical factors associated with achieving K/DOQI haemoglobin targets in hemodialysis patients. Int Urol Nephrol 2003; 35: 399–405
7. Macdougall IC, Bock A, Carrera F et al. The FIND-CKD study—a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale. Nephrol Dial Transplant 2014; 29: 843–850
8. Macdougall IC, Bock AH, Carrera F et al. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant 2014; 29: 2075–2084
9. Agarwal R, Kusek JW, Pappas MK. A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int 2015; 88: 905–914
10. Fishbane S, Frei GL, Maesaaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 1995; 26: 41–46
11. Li H, Wang SX. Intravenous iron sucrose in Chinese hemodialysis patients with renal anaemia. Blood Purif 2008; 26: 151–156
12. Li H, Wang SX. Intravenous iron sucrose in peritoneal dialysis patients with renal anaemia. Perit Dial Int 2008; 28: 149–154
13. Macdougall IC, Tucker B, Thompson J et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996; 50: 1694–1699
14. Provenzano R, Schiller B, Rao M et al. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol 2009; 4: 386–393
15. Singh H, Reed J, Noble S et al. Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anaemia: a randomized, controlled trial. Clin J Am Soc Nephrol 2006; 1: 475–482
16. Besarab A, Kaiser JW, Frinak S. A study of parenteral iron regimens in hemodialysis patients. Am J Kidney Dis 1999; 34: 21–28
17. Chang CH, Chang CC, Chiang SS. Reduction in erythropoietin doses by the use of chronic intravenous iron supplementation in iron-replete hemodialysis patients. Clin Nephrol 2002; 57: 136–141
18. Covic A, Mircescu G. The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study. Nephrol Dial Transplant 2010; 25: 2722–2730
19. DeVita MV, Frumkin D, Mittal S et al. Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients. Clin Nephrol 2003; 60: 335–340
20. KAPOIAN T, O’MARA NB, Singh AK et al. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 2008; 19: 372–379
21. Senger JM, Weiss RJ. Hematologic and erythropoietin responses to iron dextran in the hemodialysis environment. ANNA J 1996; 23: 319–323; discussion 324–315
22. Agarwal R, Rizkala AR, Bastani B et al. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol 2006; 26: 445–454
23. Agarwal HK, Nand N, Singh S et al. Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin. J Assoc Physicians India 2003; 51: 170–174
24. Charytan C, Qunibi W, Bailie GR. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract 2005; 100: c55–c62
25. Qunibi WY, Martinez C, Smith M et al. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant 2011; 26: 1599–1607
26. Spinowitz BS, Kausz AT, Baptista J et al. Ferumoxytol for treating iron deficiency anaemia in CKD. J Am Soc Nephrol 2008; 19: 1599–1605
27. Stoves J, Inglis H, Newsstead CG. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant 2001; 16: 967–974
28. Van Wyck DB, Roppolo M, Martinez CO et al. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int 2005; 68: 2846–2856
29. Fishbane S, Kalantar-Zadeh K, Nissenson AR. Serum ferritin in chronic kidney disease: reconsidering the upper limit for iron treatment. Semin Dial 2004; 17: 336–341
30. Canavese C, Berghamo D, Ciccone G et al. Validation of serum ferritin values by magnetic susceptibility in predicting iron overload in dialysis patients. *Kidney Int* 2004; 65: 1091–1098
31. Ferrari P, Kulkarni H, Dheda S et al. Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. *Clin J Am Soc Nephrol* 2011; 6: 77–83
32. Macdougall IC, Bircher AJ, Eckardt KU et al. Iron management in chronic kidney disease: conclusions from a ‘Kidney Disease: Improving Global Outcomes’ (KDIGO) Controversies Conference. *Kidney Int* 2016; 89: 28–39
33. Coyne DW, Kapoian T, Suki W et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients’ Response to IV Iron with Elevated Ferritin (DRIVE) Study. *J Am Soc Nephrol* 2007; 18: 975–984
34. Feldman HI, Joffe M, Robinson B et al. Administration of parenteral iron and mortality among hemodialysis patients. *J Am Soc Nephrol* 2004; 15: 1623–1632
35. Kalantar-Zadeh K, Regidor DL, McAllister CJ et al. Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease: conclusions from a ‘Kidney Disease: Improving Global Outcomes’ (KDIGO) Controversies Conference. *Kidney Int* 2016; 89: 28–39
36. Bhandari S, Kalra PA, Kothari J et al. Randomized, open-label trial of iron isomaltoside 1000 (Monofer(R)) compared with iron sucrose (Venofer(R)) as maintenance therapy in haemodialysis patients. *Nephrol Dial Transplant* 2015; 30: 1577–1589
37. Charytan C, Bernardo MV, Koch TA et al. Intravenous ferric carboxymaltose is efficacious in anaemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients’ Response to IV Iron with Elevated Ferritin (DRIVE) Study. *J Am Soc Nephrol* 2007; 18: 975–984
38. Feldman HI, Joffe M, Robinson B et al. Administration of parenteral iron and mortality among hemodialysis patients. *J Am Soc Nephrol* 2004; 15: 1623–1632
39. Kalantar-Zadeh K, Regidor DL, McAllister CJ et al. Time-dependent associations between iron and mortality in hemodialysis patients. *J Am Soc Nephrol* 2005; 16: 3070–3080
40. Bhandari S, Kalra PA, Kothari J et al. A randomized, open-label trial of iron isomaltoside 1000 (Monofer(R)) compared with iron sucrose (Venofer(R)) as maintenance therapy in haemodialysis patients. *Nephrol Dial Transplant* 2015; 30: 1577–1589
41. Charytan C, Bernardo MV, Koch TA et al. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study. *Nephrol Dial Transplant* 2013; 28: 953–964
42. Kalra PA, Bhandari S, Saxena S et al. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia. *Nephrol Dial Transplant* 2016; 31: 646–655
43. Onken JE, Bregman DB, Harrington RA et al. Ferric carboxymaltose in patients with iron-deficiency anaemia and impaired renal function: the REPAIR-IDA trial. *Nephrol Dial Transplant* 2014; 29: 833–842
44. Shepselovich D, Rozen-Zvi B, Avni T et al. Intravenous versus oral iron supplementation for the treatment of anaemia in kidney disease: a randomized, active-controlled, multi-center study. *Nephrol Dial Transplant* 2014; 29: 833–842
45. Rozen-Zvi B, Gafter-Gvili A, Paul M et al. Intravenous versus oral iron supplementation for the treatment of anaemia in kidney disease: a randomized, active-controlled, multi-center study. *Nephrol Dial Transplant* 2014; 29: 833–842
46. Avni T, Bieker A, Grossman A et al. The safety of intravenous iron preparations: a systematic review and meta-analysis. *Mayo Clin Proc* 2015; 90: 12–23
47. Bailie GR, Mason NA, Valaoras TG. Safety and tolerability of intravenous ferric carboxymaltose in patients with iron deficiency anaemia. *Hemodial Int* 2010; 14: 47–54
48. McMahon LP, Kent AB, Kerr PG et al. Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: a randomized controlled trial. *Nephrol Dial Transplant* 2010; 25: 920–926
49. Roger SD, Gaillard CA, Bock AH et al. Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: and analysis of the 1-year FIND-CKD trial. *Nephrol Dial Transplant* 2016 https://doi.org/10.1093/ndt/gfw264
50. Bhandari S, Kalra PA, Coyne DW. Data confusion. *Kidney Int* 2015; 88: 1445
51. Macdougall IC, Roger SD. New data on the safety of IV iron—but why the discrepancy with FIND-CKD? *Kidney Int* 2015; 88: 1445–1446
52. Agarwal R. The author replies. *Kidney Int* 2015; 88: 1446–1447
53. Brookhart MA, Freburger JK, Ellis AR et al. Comparative short-term safety of sodium ferric gluconate versus iron sucrose in hemodialysis patients. *Am J Kidney Dis* 2016; 67: 119–127
54. Freburger JK, Ellis AR, Wang L et al. Comparative effectiveness of iron and erythropoiesis-stimulating agent dosing on health-related quality of life in patients receiving hemodialysis. *Am J Kidney Dis* 2016; 67: 271–282
55. Airy M, Mandayam S, Mitani AA et al. Comparative outcomes of predominant facility-level use of ferumoxytol versus other intravenous iron formulations in incident hemodialysis patients. *Nephrol Dial Transplant* 2015; 30: 2068–2075
56. Bailie GR, Larkina M, Goodkin DA et al. Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality. *Kidney Int* 2015; 87: 162–168
57. Ishida JH, Marahfani BJ, McCulloch CE et al. Receipt of intravenous iron and clinical outcomes among hemodialysis patients hospitalized for infection. *Clin J Am Soc Nephrol* 2015; 10: 1799–1805
58. Karaboyas A, Zee J, Morgenstern H et al. Understanding the recent increase in ferritin levels in united states dialysis patients: potential impact of changes in intravenous iron and erythropoiesis-stimulating agent dosing. *Clin J Am Soc Nephrol* 2015; 10: 1814–1821
59. Kuo KL, Huang SC, Liu JS et al. Iron supplementation associates with low mortality in pre-dialyzed advanced chronic kidney disease patients receiving erythropoiesis-stimulating agents: a nationwide database analysis. *Nephrol Dial Transplant* 2015; 30: 1518–1525
60. Tangri N, Miskulin DC, Zhou J et al. Effect of intravenous iron use on hospitalizations in patients undergoing hemodialysis: a comparative effectiveness analysis from the DEcIDE-ESRD study. *Nephrol Dial Transplant* 2015; 30: 667–675
61. Freburger JK, Ellis AR, Khairisagar AV et al. Comparative short-term safety of bolus versus maintenance iron dosing in hemodialysis patients: a replication study. *BMC Nephrol* 2014; 15: 154
62. Miskulin DC, Tangri N, Bandeen-Roche K et al. Intravenous iron exposure and mortality in patients on hemodialysis. *Clin J Am Soc Nephrol* 2014; 9: 1930–1939
63. Schiller B, Bhat P, Sharma A. Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the United States over a 12-month period. *Clin Ther* 2014; 36: 70–83
64. Bailie GR, Larkina M, Goodkin DA et al. Variation in intravenous iron use internationally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS). *Nephrol Dial Transplant* 2013; 28: 2570–2579
65. Brookhart MA, Freburger JK, Ellis AR et al. Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. *J Am Soc Nephrol* 2013; 24: 1151–1158
66. Khairisagar AV, Freburger JK, Ellis AR et al. Intravenous iron supplementation practices and short-term risk of cardiovascular events in hemodialysis patients. *PloS One* 2013; 8: e78930
67. Khairisagar AV, Freburger JK, Ellis AR et al. The comparative short-term effectiveness of iron dosing and formulations in US hemodialysis patients. *Am J Med* 2013; 126: 541.e1–541.e14
68. Miskulin DC, Zhou J, Tangri N et al. Trends in anaemia management in US hemodialysis patients 2004–2010. *BMC Nephrol* 2013; 14: 264
69. Rottembourg J, Sonigo Y, Dansaert A et al. Intravenous iron during predialysis period improves anemia management and cardiovascular parameters in incident hemodialysis patients. *Nephrol Ther* 2013; 9: 486–493